Literature DB >> 23940219

Diagnosis and treatment of KIT-mutant metastatic melanoma.

Megan Lyle1, Georgina V Long.   

Abstract

A 52-year-old man has unresectable locally recurrent melanoma of the left foot (Fig 1) and pulmonary metastases. Nine months before this presentation, he underwent a wide local excision and sentinel node biopsy for an acral melanoma on his left heel. Pathology disclosed Breslow thickness of 4.8 mm, Clark level IV, and tumor ulceration with a mitotic rate of 37 mitoses/mm(2). Both sentinel nodes in the left groin were positive for melanoma cells, which expressed S100, HMB45, and melan A. At subsequent left inguinal dissection, seven more nodes showed no additional nodal metastases. Within 3 months of his original surgery, the patient developed a local recurrence in the foot, and over the subsequent 6 months, he underwent serial local excisions and topical diphencyprone treatment. A recent staging scan showed at least 20 foci of in-transit disease in the left lower leg and foot, as well as a solitary lung metastasis (12 mm). His Eastern Cooperative Oncology Group performance status is 1, with no significant comorbidities. High-resolution melt followed by sequencing of an in-transit metastasis showed there is no BRAF exon 15 mutation. However, Sanger sequencing of KIT exons 9, 11, 13, and 17, performed as screening for a clinical trial enrolling patients with metastatic acral and mucosal melanomas, showed an exon 13 K642E mutation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23940219     DOI: 10.1200/JCO.2013.50.4662

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  9 in total

Review 1.  [Molecular diagnostics in melanoma].

Authors:  R Lang; J W Bauer; M Laimer
Journal:  Hautarzt       Date:  2015-04       Impact factor: 0.751

2.  A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

Authors:  Kevin Kalinsky; Sandra Lee; Krista M Rubin; Donald P Lawrence; Anthony J Iafrarte; Darell R Borger; Kim A Margolin; Mario M Leitao; Ahmad A Tarhini; Henry B Koon; Andrew L Pecora; Anthony J Jaslowski; Gary I Cohen; Timothy M Kuzel; Christopher D Lao; John M Kirkwood
Journal:  Cancer       Date:  2017-03-23       Impact factor: 6.860

3.  MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

Authors:  Yao Zhan; Jun Guo; William Yang; Christophe Goncalves; Tomasz Rzymski; Agnieszka Dreas; Eliza Żyłkiewicz; Maciej Mikulski; Krzysztof Brzózka; Aniela Golas; Yan Kong; Meng Ma; Fan Huang; Bonnie Huor; Qianyu Guo; Sabrina Daniela da Silva; Jose Torres; Yutian Cai; Ivan Topisirovic; Jie Su; Krikor Bijian; Moulay A Alaoui-Jamali; Sidong Huang; Fabrice Journe; Ghanem E Ghanem; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2017-10-16       Impact factor: 14.808

4.  Resistance to c-Kit inhibitors in melanoma: insights for future therapies.

Authors:  Matteo S Carlino; Jason R Todd; Helen Rizos
Journal:  Oncoscience       Date:  2014-06-06

Review 5.  Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients.

Authors:  Aljosja Rogiers; Joost J van den Oord; Marjan Garmyn; Marguerite Stas; Cindy Kenis; Hans Wildiers; Jean-Christophe Marine; Pascal Wolter
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

Review 6.  Adenoid cystic carcinoma: emerging role of translocations and gene fusions.

Authors:  Piotr T Wysocki; Evgeny Izumchenko; Juliet Meir; Patrick K Ha; David Sidransky; Mariana Brait
Journal:  Oncotarget       Date:  2016-10-04

Review 7.  Novel Biomarkers and Druggable Targets in Advanced Melanoma.

Authors:  Pier Francesco Ferrucci; Emilia Cocorocchio
Journal:  Cancers (Basel)       Date:  2021-12-24       Impact factor: 6.639

8.  The Human Melanoma Proteome Atlas-Complementing the melanoma transcriptome.

Authors:  Lazaro Hiram Betancourt; Jeovanis Gil; Aniel Sanchez; Viktória Doma; Magdalena Kuras; Jimmy Rodriguez Murillo; Erika Velasquez; Uğur Çakır; Yonghyo Kim; Yutaka Sugihara; Indira Pla Parada; Beáta Szeitz; Roger Appelqvist; Elisabet Wieslander; Charlotte Welinder; Natália Pinto de Almeida; Nicole Woldmar; Matilda Marko-Varga; Jonatan Eriksson; Krzysztof Pawłowski; Bo Baldetorp; Christian Ingvar; Håkan Olsson; Lotta Lundgren; Henrik Lindberg; Henriett Oskolas; Boram Lee; Ethan Berge; Marie Sjögren; Carina Eriksson; Dasol Kim; Ho Jeong Kwon; Beatrice Knudsen; Melinda Rezeli; Johan Malm; Runyu Hong; Peter Horvath; A Marcell Szász; József Tímár; Sarolta Kárpáti; Peter Horvatovich; Tasso Miliotis; Toshihide Nishimura; Harubumi Kato; Erik Steinfelder; Madalina Oppermann; Ken Miller; Francesco Florindi; Quimin Zhou; Gilberto B Domont; Luciana Pizzatti; Fábio C S Nogueira; Leticia Szadai; István Balázs Németh; Henrik Ekedahl; David Fenyö; György Marko-Varga
Journal:  Clin Transl Med       Date:  2021-07

9.  Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.

Authors:  Alessandra Ulivieri; Giuseppe Cardillo; Liborio Manente; Gregorino Paone; Andrea Petricca Mancuso; Leonardo Vigna; Enrico Di Stasio; Rita Gasbarra; Salvatore Girlando; Alvaro Leone
Journal:  Oncotarget       Date:  2015-08-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.